Soligenix, Inc., a late-stage biopharmaceutical company focusing on rare diseases, has announced its participation in Spartan Capital Securities, LLC's inaugural investor conference. The event, scheduled for November 4th at the Pierre Hotel in New York, represents a significant opportunity for the company to present its achievements and future plans to influential figures in the capital markets. Christopher J. Schaber, PhD, President and CEO of Soligenix, expressed enthusiasm about the company's involvement, stating that this event provides an excellent platform to showcase the company and keep key influencers in the capital markets apprised of accomplishments and future plans as it moves its rare disease pipeline forward.
The conference, organized in partnership with B2i Digital, will feature presentations from over 30 carefully selected companies. It aims to foster high-level investor engagement through panel discussions, one-on-one meetings, and networking sessions. This format allows Soligenix to maximize its exposure to potential investors and industry partners. John D. Lowry, Founder and CEO of Spartan Capital Securities, LLC, highlighted the significance of the conference, stating that their inaugural investor conference commemorates Spartan Capital's 17 years as a trusted leader in the capital markets and underscores their commitment to building meaningful connections between client companies and their sophisticated investor base.
Soligenix's participation in this event is particularly noteworthy given the company's focus on developing and commercializing products for rare diseases with unmet medical needs. The company's Specialized BioTherapeutics segment is advancing HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, toward potential commercialization. With the successful completion of a second Phase 3 study, Soligenix is poised to seek regulatory approvals for worldwide commercialization. In addition to HyBryte™, Soligenix is developing other promising therapies, including synthetic hypericin for psoriasis and dusquetide for inflammatory diseases such as oral mucositis in head and neck cancer.
The company's Public Health Solutions segment is also making strides with vaccine candidates for ricin toxin, filoviruses, and COVID-19, leveraging its proprietary ThermoVax® heat stabilization platform technology. For investors and industry observers, Soligenix's participation in this conference represents an opportunity to gain insights into the company's progress and potential. As the biopharmaceutical sector continues to evolve, events like this play a crucial role in connecting innovative companies with the capital and partnerships necessary to bring new treatments to market. Interested parties can find more information about the conference and registration details on Spartan Capital's conference page. As Soligenix continues to advance its pipeline of rare disease treatments, this event may prove to be a pivotal moment in the company's journey toward bringing much-needed therapies to patients worldwide.
